Healthcare Resource Utilization and Costs Associated with Psychiatric Comorbidities in Adult Patients with Attention-Deficit/Hyperactivity Disorder

Author(s)

Schein J1, Cloutier M2, Gauthier-Loiselle M3, Bungay R2, Chen K2, Chan D2, Guérin A2, Childress A4
1Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA, 2Analysis Group, Inc., Montréal, QC, Canada, 3Analysis Group, Inc., Montreal, QC, Canada, 4Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA

OBJECTIVES: To assess the impact of psychiatric comorbidities, specifically anxiety and depression, on healthcare resource utilization (HRU) and costs in adults with attention-deficit/hyperactivity disorder (ADHD) in the United States.

METHODS: Adults with ADHD were identified in the IQVIA PharMetrics® Plus database (10/01/2015-09/30/2021). The index date was defined as the date of initiation of a randomly selected ADHD treatment. The baseline period was defined at the 6 months prior to the index date and the study period as the 12 months following the index date. Patients with ≥1 diagnosis for anxiety and/or depression during both the baseline and study periods were classified in the ADHD+anxiety/depression cohort, while those without diagnoses for anxiety nor depression at any time were classified in the ADHD-only cohort. Entropy balancing was used to create reweighted cohorts with similar baseline characteristics. All-cause HRU and healthcare costs were assessed during the study period and compared between cohorts using regression analyses.

RESULTS: After reweighting, patients in the ADHD+anxiety/depression cohort (N=217,944) and ADHD-only cohort (N=276,906) had similar characteristics (mean age 34.1 years; 54.8% male). All-cause HRU were higher in the ADHD+ anxiety/depression cohort than the ADHD-only cohort (incidence rate ratios for inpatient admissions: 4.5, emergency room visits: 1.7, outpatient visits: 2.0, and psychotherapy visits: 6.4; all p<0.01). All-cause healthcare costs were more than twice higher in the ADHD+anxiety/depression cohort than the ADHD-only cohort (mean per-patient-per-year [PPPY]: $11,315 vs. $5,335, respectively; p<0.01). Among the ADHD+anxiety/depression cohort, average all-cause healthcare costs were $9,232, $10,650, and $15,609 PPPY among patients with anxiety only, depression only, and both anxiety and depression, respectively.

CONCLUSIONS: Comingling anxiety and depression is associated with additional HRU and costs burden in patients with ADHD. Co-management of these conditions is important and has the potential to alleviate the burden experienced by patients and the healthcare system.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE138

Topic

Economic Evaluation, Study Approaches

Disease

Mental Health (including addition)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×